Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study

被引：0

作者：

Wiendl, H. ^{[1
]}

De Stefano, N. ^{[2
]}

Barkhof, F. ^{[3
]}

Montalban, X. ^{[4
]}

Achiron, A. ^{[5
]}

Derfuss, T. ^{[6
]}

Chan, A. ^{[7
]}

Hodgkinson, S. ^{[8
]}

Prat, A. ^{[9
]}

Leocani, L. ^{[10
]}

Schmierer, K. ^{[11
]}

Sellebjerg, F. ^{[12
]}

Vermersch, P. ^{[13
]}

Jin, H. ^{[14
]}

Jaervinen, E. ^{[14
]}

Chudecka, A. ^{[15
]}

Gardner, L. ^{[16
]}

机构：

[1] Univ Munster, Inst Translat Neurol, Dept Neurol, Munster, Germany

[2] Univ Siena, Dept Med Surg & Neurosci, Siena, Italy

[3] Vrije Univ Amsterdam, Dept Radiol, Med Ctr, Amsterdam, Netherlands

[4] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain

[5] Sheba Acad Med Ctr, Multiple Sclerosis Ctr, Ramat Gan, Israel

[6] Univ Hosp Basel, Dept Neurol, Basel, Switzerland

[7] Bern Univ, Univ Hosp Bern, Dept Neurol, Inselspital, Bern, Switzerland

[8] Univ New South Wales Med, Ingham Inst Appl Med Res, Sydney, Australia

[9] Univ Montreal, Dept Neurosci, Montreal, PQ, Canada

[10] Univ Vita Salute San Raffaele, Expt Neurophysiol Unit, Milan, Italy

[11] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, Ctr Neurosci Surg & Trauma, London, England

[12] Rigshosp, Dept Neurol, Danish MS Ctr, Copenhagen Univ Hosp, Glostrup, Denmark

[13] Univ Lille, INSERM, U1172, LilNCog,CHU Lille,FHU Precise, Lille, France

[14] Healthcare Business Merck KGaA, Darmstadt, Germany

[15] Cytel Inc, Geneva, Switzerland

[16] EMD Serono Inc, Billerica, MA USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P008

引用

页码：21 / 22

页数：2

共 50 条

[1] Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study
Wiendl, Heinz
De Stefano, Nicola
Barkhof, Frederik
Montalban, Xavier
Achiron, Anat
Derfuss, Tobias
Chan, Andrew
Hodgkinson, Suzanne
Prat, Alexandre
Leocani, Letizia
Schmierer, Klaus
Sellebjerg, Finn
Vermersch, Patrick
Jin, Hulin
Jarvinen, Elina
Chudecka, Anita
Gardner, Lidia
NEUROLOGY, 2023, 100 (17)
[2] Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Wiendl, Heinz
Barkhof, Frederik
Montalban, Xavier
Achiron, Anat
Derfuss, Tobias
Chan, Andrew
Hodgkinson, Suzanne
Prat, Alexandre
Leocani, Letizia
Schmierer, Klaus
Sellebjerg, Finn
Vermersch, Patrick
Jin, Hulin
Chudecka, Anita
Kloetgen, Andreas
Lin, Dongdong
Gardner, Lidia
De Stefano, Nicola
FRONTIERS IN IMMUNOLOGY, 2025, 16
[3] A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY-MS Baseline Analysis
De Stefano, Nicola
Achiron, Anat
Barkhof, Frederik
Chan, Andrew
Derfuss, Tobias
Hodgkinson, Suzanne
Leocani, Letizia
Montalban, Xavier
Prat, Alexandre
Schmierer, Klaus
Sellebjerg, Finn
Vermersch, Patrick
Wiendl, Heinz
Keller, Birgit
Roy, Sanjeev
NEUROLOGY, 2020, 94 (15)
[4] Early onset of action and sustained efficacy of MRI outcomes during cladribine tablets treatment in highly active relapsing multiple sclerosis: results of the 2-year MAGNIFY-MS study
De Stefano, N.
Achiron, A.
Barkhof, F.
Chan, A.
Derfuss, T.
Hodgkinson, S.
Leocani, L.
Montalban, X.
Prat, A.
Schmierer, K.
Sellebjerg, F.
Vermersch, P.
Wiendl, H.
Keller, B.
Smyk, A.
Gardner, L.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 629 - 631
[5] Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS Study
De Stefano, Nicola
Achiron, Anat
Barkhof, Frederik
Chan, Andrew
Derfuss, Tobias
Hodgkinson, Suzanne
Leocani, Letizia
Montalban, Xavier
Prat, Alexandre
Schmierer, Klaus
Sellebjerg, Finn
Vermersch, Patrick
Wiendl, Heinz
Keller, Birgit
Smyk, Andrzej
Gardner, Lidia
NEUROLOGY, 2023, 100 (17)
[6] A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY- MS Baseline Analysis
De Stefano, N.
Achiron, A.
Barkhof, F.
Chan, A.
Derfuss, T.
Hodgkinson, S.
Leocani, L.
Montalbant, X.
Pratt, A.
Schmierer, K.
Sellebjerg, F.
Vermersch, P.
Wiendl, H.
Keller, B.
Roy, S.
EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 685 - 686
[7] Reduction in cua mri lesions in the first 6 months of cladribine tablets treatment for highly active relapsing multiple sclerosis: magnify-ms study
De Stefano, N.
Barkhof, F.
Montalban, X.
Achiron, A.
Derfuss, T.
Chan, A.
Hodgkinson, S.
Prat, A.
Leocani, L.
Schmierer, K.
Sellebjerg, F.
Vermersch, P.
Wiendl, H.
Keller, B.
Roy, S.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 303 - 303
[8] Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis MAGNIFY-MS
de Stefano, Nicola
Barkhof, Frederik
Montalban, Xavier
Achiron, Anat
Derfuss, Tobias
Chan, Andrew
Hodgkinson, Suzanne
Prat, Alexandre
Leocani, Letizia
Schmierer, Klaus
Sellebjerg, Finn
Vermersch, Patrick
Wiendl, Heinz
Keller, Birgit
Roy, Sanjeev
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2022, 9 (04): : E1187
[9] Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis
Schmierer, Klaus
Wiendl, Heinz
Oreja-Guevara, Celia
Centonze, Diego
Chudecka, Anita
Roy, Sanjeev
Boschert, Ursula
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (13) : 2151 - 2153
[10] Stabilization of Cognitive Function in Patients With Highly Active Relapsing Multiple Sclerosis Treated With Cladribine Tablets During the 2-Year CLARIFY-MS study
Langdon, D.
Brochet, B.
Havrdova, E. K.
Lechner-Scott, J.
Montalban, X.
Patti, F.
Piehl, F.
Selmaj, K.
Solari, A.
Alexandri, N.
Nolting, A.
Lehn, A.
Smyk, A.
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 60 - 61

← 1 2 3 4 5 →